Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Biomarkers / ENG

ENG

Basics

Aliases:
This biomarker is also known as:
  • Osler-Rendu-Weber syndrome 1,
  • endoglin,
  • ORW1,
  • HHT1,
  • CD105,
  • ORW,
  • END,
  • CD105 antigen,

View in BioMuta

Description…

ENG, or endoglin, is a cell surface adhesion protein involved the regulation of angiogenesis. ENG is a major glycoprotein of the vascular endothelium and is also a component of the transforming growth factor beta receptor complex. ENG binds to the beta1 and beta3 peptides with high affinity. ENG may also be involved in preeclampsia and several types of cancer. There are several isoforms encoded by transcript variants.

Attributes

QA State: Curated
Type: Protein
Short Name:

Datasets

There are no datasets associated with this biomarker.

Organs

The following organs have data associated with this biomarker…

Breast

Attributes

Phase: Two
QA State: Under Review

Overview

Endoglin is expressed in a subset of invasive breast cancers and cell lines and is subject to epigenetic silencing by gene methylation. In a large cohort of invasive breast cancers, lack of endoglin expression in the tumor cell compartment correlates with ENG gene methylation and poor clinical outcome. (PMID:21042283)

Performance Comment

ENG was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.

Studies

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html